Axsome Therapeutics, Inc.
$184.13
▲
0.63%
2026-04-22 10:12:13
www.axsome.com
NGM: AXSM
Explore Axsome Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$9.35 B
Current Price
$184.13
52W High / Low
$191.5 / $96.09
Stock P/E
—
Book Value
$1.74
Dividend Yield
—
ROCE
-54.42%
ROE
-2.52%
Face Value
—
EPS
$-3.68
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
925
Beta
0.47
Debt / Equity
247.03
Current Ratio
1.55
Quick Ratio
1.48
Forward P/E
29.23
Price / Sales
14.27
Enterprise Value
$9.01 B
EV / EBITDA
-56.23
EV / Revenue
14.11
Rating
Strong Buy
Target Price
$223.61
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NeurAxis, Inc. | $7 | — | $80.77 M | — | -216.78% | -2.85% | $7.97 / $1.33 | $0.32 |
| 2. | Protagonist Therapeutics, Inc. | $104.42 | — | $6.74 B | — | -25.39% | -20.18% | $107.84 / $41.28 | $9.82 |
| 3. | Ensysce Biosciences, Inc. | $0.48 | — | $4.49 M | — | -355% | -3.25% | $4.85 / $0.31 | $0.7 |
| 4. | MAIA Biotechnology, Inc. | $1.41 | — | $81.91 M | — | -618.06% | -7.45% | $3.19 / $0.87 | $0.06 |
| 5. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 6. | Vor Biopharma Inc. | $15.71 | — | $810.38 M | — | -84.67% | 2057.65% | $65.8 / $2.62 | $-8.1 |
| 7. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 196 M | 170.99 M | 150.04 M | 121.46 M | 118.77 M |
| Operating Profit | -36.02 M | -32.92 M | -44.82 M | -55.47 M | -61.63 M |
| Net Profit | -28.56 M | -47.23 M | -47.97 M | -59.41 M | -74.91 M |
| EPS in Rs | -0.56 | -0.92 | -0.94 | -1.16 | -1.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 638.5 M | 385.69 M | 270.6 M | 50.04 M |
| Operating Profit | -169.24 M | -252.44 M | -182.91 M | -176.5 M |
| Net Profit | -183.17 M | -287.22 M | -239.24 M | -187.13 M |
| EPS in Rs | -3.58 | -5.61 | -4.68 | -3.66 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 689.8 M | 568.5 M | 588.24 M | 331.48 M |
| Total Liabilities | 601.51 M | 511.48 M | 397.26 M | 221.92 M |
| Equity | 88.3 M | 57.02 M | 190.98 M | 109.56 M |
| Current Assets | 588.99 M | 485.06 M | 504.26 M | 245.64 M |
| Current Liabilities | 378.84 M | 230.1 M | 138.85 M | 96.56 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -93.41 M | -128.41 M | -145.08 M | -116.51 M |
| Investing CF | -0.48 M | -0.27 M | -0.58 M | -53.7 M |
| Financing CF | 101.47 M | 57.84 M | 331.01 M | 284.58 M |
| Free CF | -93.89 M | -128.68 M | -145.66 M | -117.21 M |
| Capex | -0.48 M | -0.27 M | -0.58 M | -0.7 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 42.53% | 440.8% | — | — |
| Earnings Growth % | -20.05% | -27.84% | — | — |
| Profit Margin % | -74.47% | -88.41% | -373.99% | — |
| Operating Margin % | -65.45% | -67.59% | -352.74% | — |
| Gross Margin % | 91.37% | 90.37% | 89.61% | — |
| EBITDA Margin % | -70.68% | -83.15% | -350.53% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.